Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2009
December 1, 2009
- Study Tests Blood Pressure Drugs for Diabetics
- Court Hears Vioxx Lawsuit Arguments
- Swiss Fine Drug Firms $5.7M for Price-Fixing
- Pfizer Signs Development Deal With Protalix
- WHO Approves Glaxo's Swine Flu Shot
- Drug-Industry Bosses Give Job-Seekers Advice
- Glaxo Takes 19 Percent Stake In Aspen
- Abbott gives Teva TriCor rights as early as 2011
- GSK completes extension of strategic collaboration with Aspen
- Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
- Former Johnson & Johnson Exec Charged in Britain
- Pfizer to Start Selling Generic Drugs in Japan
December 2, 2009
- FDA Approves OTC Version of Heartburn Drug Zegerid
- Pfizer Inks Deal for New Drugmaking Technology
- Genzyme Resumes Some Shipments at Mass. Facility
- Dyax Gets FDA Approval For Genetic Disorder Drug
- Keryx Treatment Gets Faster FDA Review
- CytRx: FDA Lifts 2-Year Hold on Arimoclomol Tests
- Takeda to Continue Strategic Expansion with Operations in Brazil
- Watson Completes $1.75 Billion Buyout of Arrow
- Takeda Pharmaceutical to Launch Sales Unit in Brazil in Feb.
December 3, 2009
- Norpramin (desipramine hydrochloride) - Dear Healthcare Professional Letter
- Cephalon Sues Teva Over Sleep Drug Nuvigil
- Targacept, Astrazeneca Cooperate On Depression Med
- KV Make Van Vliet Permanent President and CEO
- Cephalon Sues Teva Over Sleep Drug Nuvigil
- Pfizer's Kindler Warns Against Fueling Public's Anger
- Bayer wins Chinese approval for multiple sclerosis drug
- FDA approves Zegerid for OTC treatment
- CBO Report: Promotional Spending for Prescription Drugs
- Lexiva (fosamprenavir calcium) - Dear Healthcare Professional Letter: Association between Lexiva and myocardial infarction in HIV infected adults
December 4, 2009
- Information for Healthcare Professionals: Risk of Neural Tube Birth Defects following prenatal exposure to Valproate
- Consumer Advocate Asks FDA to Ban Weight Loss Pill
- Glaxo's Swine Flu Shot May Give Kids Fever
- Watson Challenges Takeda's Rozerem Patent
- AstraZeneca Drug Wins Partial US Approval
- NJ Gov.-Elect Christie Names Pfizer Exec as Chief of Staff
- ICON Receives Warning Letter Relating to Two Studies
- Tighter controls recommended to prevent conflicts of interest between doctors and pharmaceutical companies
- MiddleBrook Pharmaceuticals Reduces Field Sales Force and Corporate Staff, Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement
- Drug Makers, FDA Move To Curb Painkiller Abuse
- Governor-Elect Chris Christie Announces Rich Bagger as Chief of Staff
December 7, 2009
- Bristol-Myers Squibb, Pfizer to Seek European Approval for apixaban in H1 '10
- Bristol-Myers Squibb, Pfizer to Seek European Approval for apixaban in H1 '10
- Drugmakers' Support for Health Overhaul Tested
- Genmab Announces RG1507 Update
- Teva Seen Among Leaders For Ratiopharm
- Amgen Approves $5 Billion Stock Buyback
- Valeant Pharma Will Buy Laboratoire Dr. Renaud
- La Jolla Pharmaceutical Company Announces Signing of Definitive Merger Agreement With Adamis Pharmaceuticals
- FDA Approves Lilly Antipsychotic for Teens
December 8, 2009
- Drug Manufacturer Expanding in Louisiana
- Changes to CSL Senior Executive Group
- AstraZeneca to Cover Copays for Some Patients
- Dr. Reddy's Expanding in Louisiana
- Tranzyme to Research Drugs for Bristol-Myers
- Drug Company Makes Big Deal
- Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR
- Quintiles Staying Quiet About Bond Sales
- Antidepressant May Change Personality While Relieving Symptoms
- U.S. Firms Warned Against Bioterror Threat
- Pfizer And Crown Bioscience Announce A Collaboration To Research And Develop New Treatments For Asian Cancers
December 9, 2009
- Drug-import Backers Worry Obama May Scuttle Plan
- Analyst: Pharma Profit Will Fall on Patent Losses
- Genzyme Appoints Robert Bertolini to Board of Directors
- British Researchers Say Little Evidence Tamiflu Works, but WHO Says the Drug is Useful
- Unigene Announces Significant Cost Savings and Corporate Restructuring
- Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases
- Eli Lilly To Sell Hospitals Smaller Insulin Vials
- EU Raids Drug Makers in Antitrust Probe
- BioCryst Elects ex-Glaxo and Squibb Exec to Board
December 10, 2009
- Eli Lilly Sees Growth in Earnings Next Year
- Showdown US Vote Nears on Importing Low-cost Drugs
- Cytokinetics Ends Cancer Deal with GlaxoSmithKline
- Dendreon Names Hans Bishop Chief Operating Officer
- GAO: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed
- Sanofi-Aventis And U.S Biotechnology Company Alopexx Enter Into A Collaboration Agreement For A Novel Human Monoclonal Antibody Targeting Infectious Diseases
- Glaxo Plans To Beat Rivals In Emerging Markets
- Facet Board Recommends Rejection Of Biogen Bid
- Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
- Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
December 11, 2009
- Sens. Move to Block Drug Makers from Mining Rx Data
- Gilead Moves Closer to US Approval of CF Treatment
- Studies: Bone Drugs May Help Prevent Breast Cancer
- Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)
- Pfizer Children's Vaccine Receives European OK
- Pfizer Receives European Authorization For Prevenar 13 for the Prevention of Pneumococcal Disease In Infants and Young Children
- Pfizer Extends Medication Giveaway For Jobless
- Nymox Pharmaceuticals Gets $15M Financing Deal
- Sanofi, Alopexx Developing Infection Treatment
- Seattle Genetics, Genentech End Cancer Partnership
- Biotec Pharmacon Realigns Strategy and Reduces Workforce
- FDA Confirms Benefits of Crestor In More Patients
- Report: SEC Probing Insider-Trading Allegations
December 14, 2009
- Novel Drug Combo Improves Breast Cancer Survival
- Bristol-Myers Squibb Announces Appointment of Charles Bancroft as Acting Chief Financial Officer
- Roche Cuts Short Heart Failure Study
- Lilly's Earnings Outlook Sparks Stock Sell-Off
- Sanofi Plans Layoffs At Swiftwater
- GTx Announces Reduction in Force
- Alcon to Enter Surgical Glaucoma Market by Acquiring Optonol
- Bristol-Myers Chief Financial Officer to Leave
- FDA OKs Longer-Lasting Version Of Lilly's Zyprexa
December 15, 2009
- Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
- Addex Pharmaceuticals (CH) - Addex ends migraine prevention study
- Addex Pharmaceuticals (CH) - Development of ADX10059 ended for long-term use
- Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpoints
- Blood Pressure Drug Candidate Falls Short In Trial
- Amgen, Array BioPharma Enter Development Agreement
- Teva Hails Milder Restrictions On Parkinson's Drug
- 800,000 Doses Of Kids' Swine Flu Vaccine Recalled
- Takeda and Pfizer to Co-Promote Takeda's Actos (Pioglitazone HCl) for the Treatment of Type 2 Diabetes in China
- Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease
December 16, 2009
- Senate Kills Drug Re-importation
- Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
- Senate Rejects Plan to Import Low-Cost Drugs
- FDA Panel Backs New Use For Astrazeneca's Crestor
- Biogen Threatens Proxy Fight In Facet Bid
- Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog
- Favorable Vote from FDA Advisory Committee on Benefit/Risk of Crestor (rosuvastatin calcium) in JUPITER Study
- FDA Approves Generic Aricept to Treat Dementia Related to Alzheimer's Disease
- Merck Appoints Dr. Michael Rosenblatt As Executive Vice President & Chief Medical Officer
- Bristol-Myers Squibb Sets Exchange Ratio of 0.6313 for the Exchange Offer
- Auxilium Reports Positive Mid-Stage Study Results
- Bristol-Myers Sets Exchange Ratio for Offering
- IMS Health Sets Feb. 8 Date For Buyout Vote
- Celgene Psoriasis Drug Meets Midstage Study Goal
December 17, 2009
- Democrats Vow to Close Medicare 'doughnut hole'
- FDA Panel Votes Down New Use for OSI Cancer Drug
- Merck & Co., Inc. to Acquire Avecia Biologics
- Merck Names Tufts Dean As Chief Medical Officer
- Senators: Drug Makers Will Pay More For Health Bill
- GlaxoSmithKline Plans to Rehire 40 To 50 Employees in Tennessee Plant
- deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin
December 18, 2009
- Amgen's Prolia Moves Closer to European Approval
- Vion Pharmaceuticals Files for Chapter 11 Bankruptcy
- New Cook Pharmica Plant Needs 115 New Workers
- CEO Sees Belgo-Dutch Galapagos As Potential Takeover Target
- Hawaii Biotech Coup Fails
- Thallion Discontinues Phase II Glioblastoma Multiforme Trial After Review of Interim Data
- Eisai Initiates Procedures to Acquire AkaRx, Inc. in the United States
- Pharmalive.Com Releases Report of Best Pharmaceutical & Biotechnology Pipelines; Announces Most Promising Pipeline for 2010
December 21, 2009
December 22, 2009
- Sanofi-Aventis Agrees to Buy US Healthcare Company Chattem for $1.9 Billion
- QLT Inc. Establishes Sales Force in the United States
- Dr. Julie Gerberding Named President of Merck Vaccines
- FDA: Review Finds no Proof Vytorin Causes Cancer
- ZymoGenetics and Bayer Restructure Recothrom Agreements
December 23, 2009
- Novartis to Acquire Corthera Inc., Gaining Worldwide Rights to Phase III Project Relaxin for Treatment of Acute Decompensated Heart Failure
- The Medicines Company Acquires ApoA-I Milano From Pfizer
- Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial
- Lupin Announces Litigation Settlement with Forest for Memantine Tablets
- Amgen Resolves EPO Patent Dispute With Roche
- Novexel to be Acquired by AstraZeneca
